Christine A. Carberry insider trades: Keryx Biopharmaceuticals (KERX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christine reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 11, 2018 | KERX | ↓ Sell | 10,469 | $3.22 | $34K | Direct | Dec 13, 2018 (2d) |
| Oct 18, 2018 | KERX | ↓ Sell | 2,040 | $3.29 | $7K | Direct | Oct 22, 2018 (4d) |
| Jul 18, 2018 | KERX | ↓ Sell | 2,021 | $4.49 | $9K | Direct | Jul 19, 2018 (1d) |
| Apr 18, 2018 | KERX | ↓ Sell | 2,026 | $4.83 | $10K | Direct | Apr 20, 2018 (2d) |
| Jan 18, 2018 | KERX | ↓ Sell | 9,048 | $4.87 | $44K | Direct | Jan 22, 2018 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Christine A. Carberry's insider trades
Christine A. Carberry is Chief Operating Officer at Keryx Biopharmaceuticals (KERX). Since Jan 18, 2018, Christine has reported no open-market purchases and 5 sales worth $103K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KERX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.